Skip to main content

Table 1 R&D efficiencies of multinational pharmaceutical companies (2006–2014)

From: Changing R&D models in research-based pharmaceutical companies

  Total R&D expenditures (USD million) (2006–2014) Number of FDA approved NMEs (2006–2014) R&D efficiency (USD million/NME) (2006–2014)
Abbott/Abbvie 31,292 1 31,292
Eli Lilly 40,232 4 10,058
Roche 78,340 9 8704
Sanofi 42,948 6 7158
Merck & Co. 62,745 9 6972
Pfizer 72,125 11 6557
AstraZeneca 45,081 7 6440
Novartis 72,100 13 5546
Amgen 30,437 6 5073
GSK 47,109 12 3926
Takeda 23,361 6 3893
Bristol-Myers Squibb 33,006 9 3667
Boehringer Ingelheim 22,920 7 3274
  1. Merck & Co including Schering Plough (starting 2009), Pfizer including Wyeth (starting 2009), Roche including Genentech (starting 2010), Novartis including Alcon (starting 2010), Sanofi including Genzyme (starting 2011)
  2. Source: Annual company reports, http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/UCM081805.pdf